Drug Profile
Research programme: RGD peptides - GlaxoSmithKline
Latest Information Update: 27 Feb 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 24 Mar 1999 Preclinical development for Cancer in United Kingdom (unspecified route)